Abatacept in the treatment of rheumatoid arthritis

Augusto Posadas, Jeffrey R Lisse, Sujata Sarkar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory arthritis affecting 1% of the population. The immunologic dysfunction underlying this immune disorder is complex and intricate with the involvement of various immune cells as well as cytokines and surface molecules. While inhibition of TNF-α has changed the outlook of patients with this disorder, it regulates only one aspect of the inflammatory cascade associated with RA. This is corroborated by experience in the clinic, where a significant proportion of the patients do not have clinical benefit with such therapies. Furthermore, a number of patients experience blunting of the initial therapeutic benefits of TNF-α-targeted therapies. Thus, a different approach to regulate the immune dysfunction associated with RA is necessary. T cells are considered important in the pathogenesis of RA and abatacept, a fusion protein, was developed to abolish the activation of the T cell by blocking its interaction with the antigen-presenting cell. Abatacept has demonstrated promising clinical improvements in patients with RA. Although clinical experience with this new drug is limited and its mechanism of action remains to be understood, the data on the safety profile are reassuring.

Original languageEnglish (US)
Pages (from-to)9-17
Number of pages9
JournalExpert Review of Clinical Immunology
Volume5
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Rheumatoid Arthritis
T-Lymphocytes
Therapeutics
Immune System Diseases
Antigen-Presenting Cells
Arthritis
Abatacept
Cytokines
Safety
Pharmaceutical Preparations
Population
Proteins

Keywords

  • Abatacept
  • Biologic therapy
  • CTLA4Ig
  • Rheumatoid arthritis
  • T cell

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Abatacept in the treatment of rheumatoid arthritis. / Posadas, Augusto; Lisse, Jeffrey R; Sarkar, Sujata.

In: Expert Review of Clinical Immunology, Vol. 5, No. 1, 2009, p. 9-17.

Research output: Contribution to journalArticle

Posadas, Augusto ; Lisse, Jeffrey R ; Sarkar, Sujata. / Abatacept in the treatment of rheumatoid arthritis. In: Expert Review of Clinical Immunology. 2009 ; Vol. 5, No. 1. pp. 9-17.
@article{04f0aa7ccfa74715b107954f76ccf5f3,
title = "Abatacept in the treatment of rheumatoid arthritis",
abstract = "Rheumatoid arthritis (RA) is a chronic inflammatory arthritis affecting 1{\%} of the population. The immunologic dysfunction underlying this immune disorder is complex and intricate with the involvement of various immune cells as well as cytokines and surface molecules. While inhibition of TNF-α has changed the outlook of patients with this disorder, it regulates only one aspect of the inflammatory cascade associated with RA. This is corroborated by experience in the clinic, where a significant proportion of the patients do not have clinical benefit with such therapies. Furthermore, a number of patients experience blunting of the initial therapeutic benefits of TNF-α-targeted therapies. Thus, a different approach to regulate the immune dysfunction associated with RA is necessary. T cells are considered important in the pathogenesis of RA and abatacept, a fusion protein, was developed to abolish the activation of the T cell by blocking its interaction with the antigen-presenting cell. Abatacept has demonstrated promising clinical improvements in patients with RA. Although clinical experience with this new drug is limited and its mechanism of action remains to be understood, the data on the safety profile are reassuring.",
keywords = "Abatacept, Biologic therapy, CTLA4Ig, Rheumatoid arthritis, T cell",
author = "Augusto Posadas and Lisse, {Jeffrey R} and Sujata Sarkar",
year = "2009",
doi = "10.1586/1744666X.5.1.9",
language = "English (US)",
volume = "5",
pages = "9--17",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Abatacept in the treatment of rheumatoid arthritis

AU - Posadas, Augusto

AU - Lisse, Jeffrey R

AU - Sarkar, Sujata

PY - 2009

Y1 - 2009

N2 - Rheumatoid arthritis (RA) is a chronic inflammatory arthritis affecting 1% of the population. The immunologic dysfunction underlying this immune disorder is complex and intricate with the involvement of various immune cells as well as cytokines and surface molecules. While inhibition of TNF-α has changed the outlook of patients with this disorder, it regulates only one aspect of the inflammatory cascade associated with RA. This is corroborated by experience in the clinic, where a significant proportion of the patients do not have clinical benefit with such therapies. Furthermore, a number of patients experience blunting of the initial therapeutic benefits of TNF-α-targeted therapies. Thus, a different approach to regulate the immune dysfunction associated with RA is necessary. T cells are considered important in the pathogenesis of RA and abatacept, a fusion protein, was developed to abolish the activation of the T cell by blocking its interaction with the antigen-presenting cell. Abatacept has demonstrated promising clinical improvements in patients with RA. Although clinical experience with this new drug is limited and its mechanism of action remains to be understood, the data on the safety profile are reassuring.

AB - Rheumatoid arthritis (RA) is a chronic inflammatory arthritis affecting 1% of the population. The immunologic dysfunction underlying this immune disorder is complex and intricate with the involvement of various immune cells as well as cytokines and surface molecules. While inhibition of TNF-α has changed the outlook of patients with this disorder, it regulates only one aspect of the inflammatory cascade associated with RA. This is corroborated by experience in the clinic, where a significant proportion of the patients do not have clinical benefit with such therapies. Furthermore, a number of patients experience blunting of the initial therapeutic benefits of TNF-α-targeted therapies. Thus, a different approach to regulate the immune dysfunction associated with RA is necessary. T cells are considered important in the pathogenesis of RA and abatacept, a fusion protein, was developed to abolish the activation of the T cell by blocking its interaction with the antigen-presenting cell. Abatacept has demonstrated promising clinical improvements in patients with RA. Although clinical experience with this new drug is limited and its mechanism of action remains to be understood, the data on the safety profile are reassuring.

KW - Abatacept

KW - Biologic therapy

KW - CTLA4Ig

KW - Rheumatoid arthritis

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=77649106299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649106299&partnerID=8YFLogxK

U2 - 10.1586/1744666X.5.1.9

DO - 10.1586/1744666X.5.1.9

M3 - Article

C2 - 20476895

AN - SCOPUS:77649106299

VL - 5

SP - 9

EP - 17

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 1

ER -